INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET

Company Participants

David Moss - Chief Financial Officer

RJ Tesi - Chief Executive Officer

Mark Lowdell - Chief Scientific Officer

Conference Call Participants

Joel Beatty - Baird

Tom Shrader - BTIG

Daniel Carlson - Tailwinds Research

Operator

Greetings and welcome to the INmune Bio Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder this conference is being recorded. A transcript will follow within 24 hours of this conference call.

At this time, it is my pleasure to introduce Mr. David Moss, CFO of INmune Bio. David, the floor is yours.

David Moss

Thank you, Claudia, and good afternoon everybody. We thank you for joining us for INmune Bio's third quarter 2023 financial results. With me on the call is RJ Tesi, CEO of INmune Bio and Mark Lowdell, Chief Scientific Officer of INmune Bio who will provide an update on INKmune our memory-like natural killer cell oncology platform.

Before we begin, I remind everyone that except for statements of historical fact, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.

Please see the forward-looking statements disclaimer on the company's earnings press release, as well as risk factors in the company's SEC filings including our most recent quarterly filings with the SEC. There is no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligations to update these forward-looking statements to reflect future information events or circumstances.

With that behind us, now I'd like to turn the call over to Dr. RJ Tesi, CEO of INmune Bio RJ?

RJ Tesi

Thank you, David, and thank you everyone for joining the call. As usual I will arrange my remarks to highlight the key takeaways for the third quarter and the subsequent period and include updates on our platform programs. I will start by reviewing our developments of XPro before passing it over to Mark Lowdell who will provide an update on INKmune. And then David Moss will continue conclude with a discussion of our financial results, and provide an update on upcoming and new milestones then we move to Q&A.